Clinical Trials
78 trialsEfficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC
Innovent Biologics (Suzhou) Co. Ltd.
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
H. Lee Moffitt Cancer Center and Research Institute
Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
Mayo Clinic
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
BeiGene
MEK162
University Health Network, Toronto
Pharmaco-economic Study of a Second Line Treatment in Advanced Non Small Cell Lung Cancer
University Hospital, Limoges
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
Inspirna, Inc.
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
Novartis
LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
Novartis
ZEAL
Sanofi
Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer
BeiGene
Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)
SWOG Cancer Research Network
A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
Cantargia AB
Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer
Eisai Inc.
Cisplatin, Pemetrexed Disodium, and Radiation Therapy Followed by Docetaxel in Treating Patients With Stage III Non-Small Cell Lung Cancer
Barbara Ann Karmanos Cancer Institute
MODEL
Intergroupe Francophone de Cancerologie Thoracique
First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC
SCRI Development Innovations, LLC
Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer
SCRI Development Innovations, LLC
Study of Participants With Advanced Non-Small Cell Lung Cancer
Eli Lilly and Company
APICAL
Chonnam National University Hospital
Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.
Swiss Cancer Institute
A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer
BioNTech SE
Safety of Everolimus and Pemetrexed in Lung Cancer Patients
Novartis
Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC
Massachusetts General Hospital
NVALT10
Dutch Society of Physicians for Pulmonology and Tuberculosis
DENALI
Mereo BioPharma
A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC
Jiangsu HengRui Medicine Co., Ltd.
Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors
Bayer
0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer
University of Maryland, Baltimore
A Study in Non-Small Cell Lung Cancer
Eli Lilly and Company
A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
Eli Lilly and Company
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Northwestern University
Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).
Swiss Cancer Institute
BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer
M.D. Anderson Cancer Center
Pemetrexed Disodium and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Mayo Clinic
Clinical Study of Chinese Medicine Plus Chemotherapy Maintenance in Advanced Non Small Cell Lung Cancer
Shanghai University of Traditional Chinese Medicine
Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
University of California, Davis
Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)
Memorial Sloan Kettering Cancer Center
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
EMD Serono
Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON)
Memorial Sloan Kettering Cancer Center
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers
UNC Lineberger Comprehensive Cancer Center
Pemetrexed Disodium and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
Roswell Park Cancer Institute
CBP08-02
CanBas Co. Ltd.
Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
University of Washington
Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer.
H. Lee Moffitt Cancer Center and Research Institute
Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Trial of Bevacizumab in Combination With Pemetrexed
Stanford University
Single Agent Alimta in Poor Performance Status in Non-small Cell Lung Cancer
M.D. Anderson Cancer Center